Strikingly, treatment of NSG mice-transplanted primary patient B-ALL (primary B-ALL) but not healthy CD19+ cells purified from the blood of healthy donors resulted in significant BODIPY C11 accumulation following volasertib treatment (Fig. 4D). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.